SEC Form 4 · accession 0001209191-17-029545
Epizyme, Inc. · EPZM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert A Copeland
Officer — President of Research and CSO
Period of report
May 2, 2017
Accepted (ET)
May 3, 2017 · 1:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001571498
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Commons Stock, par value $0.0001 | May 2, 2017 | M | 5,000 | $3.54 | A | 36,538 | D | |
| Commons Stock, par value $0.0001F1 | May 2, 2017 | S | 5,000 | $17.4425 | D | 31,538 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $3.54 | May 2, 2017 | M | 5,000 | D | — | Jan 24, 2023 | Common Stock | 5,000 | 38,550 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.40 per share to $17.65 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F3This option is fully vested.